Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
The safety profile was consistent with Part 1 of the study with amlitelimab being well-tolerated and no new safety concerns identified.
- The safety profile was consistent with Part 1 of the study with amlitelimab being well-tolerated and no new safety concerns identified.
- Overall rates of treatment-emergent adverse events (TEAEs) were 69.8% for continued amlitelimab treatment, 71.9% for the amlitelimab withdrawal-arm and 66.7% for placebo.
- TEAEs more commonly observed included headache (11.6% amlitelimab continuation, 3.9% amlitelimab withdrawal, 6.7% placebo), upper respiratory tract infection (9.3% amlitelimab continuation, 5.5% amlitelimab withdrawal, 20% placebo).
- Amlitelimab is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority.